Saurabh Chhabra, MD
Hematology & Oncology · Scottsdale, AZNPI 1689837379
Payments from drug & device makers
Across 285 payments — averaging $22,868 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$3.9M
- AbbVie$1.3M
- AstraZeneca$318K
- GSK$283K
- Incyte Corporation$137K
- Sanofi US Services Inc.$123K
- plus $416K from 21 others
Across 10 payments — averaging $527.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$5K
- AbbVie$223
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 36 | $3,926,759 |
| AbbVie | 63 | $1,314,414 |
| AstraZeneca | 9 | $318,006 |
| GSK | 9 | $283,232 |
| Incyte Corporation | 32 | $136,713 |
| Sanofi US Services Inc. | 11 | $122,535 |
| Bristol Myers Squibb | 5 | $119,327 |
| Janssen Research & Development, LLC | 32 | $110,788 |
| National Marrow Donor Program | 5 | $63,000 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $33,984 |
| Novartis | 2 | $28,533 |
| Sanofi | 15 | $19,626 |
| Sanofi-aventis U.S. LLC | 16 | $19,486 |
| Johnson & Johnson | 3 | $6,660 |
| Pfizer | 6 | $3,992 |
| Sobi, Inc | 2 | $2,975 |
| Legend Biotech USA Inc. | 1 | $2,108 |
| Adaptive Biotechnologies Corporation | 19 | $1,804 |
| Daiichi Sankyo Inc. | 2 | $1,010 |
| E.r. Squibb & Sons, L.L.C. | 1 | $955 |
| Beigene USA, Inc. | 1 | $675 |
| Cardinal Health 110 LLC | 2 | $375 |
| Janssen Scientific Affairs, LLC | 2 | $300 |
| Genmab U.S., Inc. | 1 | $55 |
| Rigel Pharmaceuticals, Inc. | 1 | $28 |
| The Binding Site Inc. | 1 | $25 |
| Genentech USA, Inc. | 1 | $25 |
How this compares
$6,517,391 in reported general payments places this provider in the 95th percentile of 261 hematology & oncology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Scottsdale
- Tanios Bekaii-SaabScottsdale$31.4M
- Yousef ZakhariaScottsdale$13M
- Parminder SinghScottsdale$9.7M
- Michael GordonScottsdale$9.2M
- Daniel AhnScottsdale$9.1M
- Mitesh BoradScottsdale$3.6M
- Peter BergsagelScottsdale$3.6M
- Cassandra MooreScottsdale$3.5M
- Alexander StewartScottsdale$3.2M
- Christopher DisimoneScottsdale$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.